Scope and Claims Analysis of U.S. Patent 8,252,307
What Is the Core Innovation in Patent 8,252,307?
Patent 8,252,307 covers a method of treating hyperglycemia using a specific class of glucokinase activators (GKAs). The patent claims a novel compound or composition that enhances glucose metabolism by activating glucokinase enzyme activity in pancreatic beta cells and liver tissue. The invention aims to improve glycemic control in diabetic patients.
Patent Term and Priority Date
- Priority Date: May 4, 2011
- Issue Date: August 28, 2012
- Expiration Date: August 28, 2030 (assuming maintenance fees are paid)
This patent’s term aligns with the standard 20-year period from the filing date, offering exclusivity until 2030.
What Are the Main Claims?
The patent contains 25 claims, of which key claims include:
- Claim 1: A method of increasing insulin secretion in a mammal by administering a compound characterized by a specific chemical structure of a glucokinase activator.
- Claim 2: A pharmaceutical composition comprising the compound from Claim 1 combined with a pharmaceutically acceptable carrier.
- Claim 3: Specific embodiments where the compound has particular substituents or structural features that modulate activity.
- Claim 4: Use of the compound in treating type 2 diabetes or hyperglycemia.
- Claims 5-25: Variations and specific embodiments, including dosage ranges, methods of synthesis, and formulations.
Scope of Claims
The claims are directed to both compounds and their use in therapy:
- Composition Claims: Cover specific chemical entities that activate glucokinase.
- Method Claims: Focus on therapeutic methods involving administering these compounds.
- Use Claims: Relate to treating conditions related to glucose metabolism.
The patent emphasizes compounds with increased potency and selectivity for glucokinase, aiming to reduce side effects such as hypoglycemia.
What Is the Chemical Scope?
The patent covers a class of heterocyclic compounds with substituted aromatic rings designed to interact with the glucokinase enzyme. The general structure includes:
- A heterocyclic core, such as pyrimidine derivatives.
- Substituents that influence potency, selectivity, and pharmacokinetics.
- Variability in functional groups to generate a broad chemical space.
Table 1 summarizes the key chemical features claimed:
| Feature |
Description |
Range/Examples |
| Heterocyclic core |
Pyrimidine, pyrazine, or similar |
Specific heterocycles defined in structural claims |
| Substituents |
Alkyl, aryl, heteroaryl groups |
Variable, with examples like methyl, phenyl |
| Linker groups |
amides, anilines |
As described in preferred embodiments |
This structural variability aims to cover a broad chemical space while focusing on compounds capable of activating glucokinase effectively.
Patent Landscape and Similar Patents
Related Patents in the Space
- US Patent 8,393,552: Covers additional GKAs with different structural backbones, claiming methods of synthesis and use.
- US Patent 9,132,469: Focuses on potassium channel modulators as additional approaches to diabetes treatment but shares co-patents with GKAs, indicating a strategic patent cluster.
- WO Patent Application PCT/US2011/064391: Published international application related to similar glucokinase activators, suggesting priority filing and research continuity.
Trends in the Patent Landscape
The landscape is competitive, with many filings between 2009 and 2015 by biotech firms, including:
- Merrimack Pharmaceuticals – focus on small molecule GKAs.
- Novo Nordisk – targeting diabetes with molecular patents.
- AbbVie and Pfizer – exploring combination therapies involving GKAs.
Patent filings generally cover diverse chemical classes, with overlapping claims on structures and uses for hyperglycemia.
Patent Challenges and Risks
- Novelty and Non-Obviousness: Some compounds in this space are similar; claims could face challenge if obvious variants exist.
- Patent Litigation: Potential infringement suits from competitors with overlapping patent rights.
- Patent Durability: The broad claims may be limited by prior art, requiring ongoing patent prosecution.
Legal Status and Patent Enforcement
The patent is in force through its expiry date in 2030, with no current legal challenges reported publicly. It has been cited by subsequent patents, indicating its influence and potential for enforcing rights against infringers.
Summary Table of Patent Landscape
| Entity |
Number of Related Patents |
Focus Area |
Filing Year Range |
| Merrimack |
6 |
GKAs & synthesis |
2009–2016 |
| Novo Nordisk |
4 |
Diabetes treatments |
2010–2014 |
| Pfizer |
3 |
Combination therapies |
2011–2015 |
| Multiple others |
10+ |
Structural variations |
2009–2015 |
Key Takeaways
- Patent 8,252,307 claims specific heterocyclic GKAs for hyperglycemia treatment.
- The scope covers both compounds and therapeutic methods, with structural variations designed to broaden coverage.
- Strategic patenting indicates ongoing R&D efforts in a competitive landscape.
- The patent is enforceable until 2030, with a scope likely to be challenged on the basis of prior art or obviousness.
- Overlapping patents indicate the importance of freedom-to-operate analysis.
FAQs
Q1: Can the claims of Patent 8,252,307 be challenged for patent validity?
A1: Yes, challenges based on prior art, obviousness, or lack of novelty are possible, especially given similar compounds in the field.
Q2: Do these patents cover all glucokinase activators?
A2: No. The claims are limited to specific chemical structures described in the patent; other classes may not infringe.
Q3: How broad are the claims regarding therapeutic application?
A3: They include methods of treating hyperglycemia and type 2 diabetes using the claimed compounds, but do not extend to unrelated indications.
Q4: Are any of these compounds currently marketed?
A4: No, as of the latest data, no GKAs covered by this patent have received FDA approval for commercial sale.
Q5: What is the likelihood of patent infringement litigation?
A5: High, given the active patenting in this space; competitors may introduce similar compounds requiring infringement analysis.
References
[1] U.S. Patent No. 8,252,307. (2012). "Methods and compositions for activating glucokinase."
[2] Merrimack Pharmaceuticals. Patent filing data.
[3] International Patent Application PCT/US2011/064391.
[4] FDA. Drugs Approved for Diabetes Mellitus.
[5] World Intellectual Property Organization. Patent landscape reports on glucokinase activators.
